Idiopathic Generalized Epilepsy Syndromes

Idiopathic Generalized Epilepsy Syndromes: Clinical Features and Long-term Outcomes

The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA). Recognition of the IGEs is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (ASMs), and provides prognostic guidance.

According to the new ILAE definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.

Study Overview

• Status: Recruiting
• Conditions: Epilepsy; Epilepsy, Idiopathic Generalized

Detailed Description

the Long-term prognosis include the rate of drug-resistent epilepsy, relapse after drug withdrawn, common comorbidities such as mood disorders, attention deficit hyperactivity disorder (ADHD) and learning disabilities.

• Study Type: Observational
• Enrollment (Estimated): 200

Contacts and Locations

• Study Contact: Name: Chunhong Shen; Phone Number: +86 0571 87783872; Email: shen_neurology@zju.edu.cn

Study Locations

• China
  • Zhejiang
    • Hangzhou, Zhejiang, China, 310000
      • Recruiting
      • 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
      • Contact: Chunhong Shen; Phone Number: +86 0571 87783872; Email: shen_neurology@zju.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

Patients are consecutively and prospectively recruited from epilepsy center and clinics

Description

Inclusion Criteria:

• Patients are consecutively and prospectively enrolled from epilepsy center, with newly diagnosed epilepsy or established epilepsy.
• Patients have a diagnosis of idiopathic generalized epilepsy (IGE), according to the 2022 diagnostic criteria.
• Comprehensive clinical information is collected, and 24 hour video-electroencephalography is performed.
• Sign the informed consent forms.

Exclusion Criteria:

• Other epilepsy syndromes are considered during follow-up, such as genetic generalized epilepsy.
• Lost to follow-up

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The proportion of drug-resistent epilepsy	We defined drug-resistant cases as those patients who have failed two or more trials of broad-spectrum ASMs or those otherwise indicated in IGE syndromes	through study completion, an average of 1 year
The proportion of seizure freedom	We defined seizure freedom according to the International League Against Epilepsy (ILAE) definition	through study completion, an average of 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The proportion of psychiatric comorbidity	The psychiatric comorbidities mainly include anxiety and depression, which are evaluated by Hamilton anxiety scale and Hamilton depression scale, respectively.	through study completion, an average of 1 year
The proportion of psychosocial outcome	such as university entrance, marry	through study completion, an average of 1 year
The proportion of seizure relapse after antiseizure medication withdrawn	Antiseizure medication withdrawn should be recommended by epilepsy experts	through study completion, an average of 1 year

Collaborators and Investigators

• Sponsor: Shen Chun-Hong
• Investigators: Principal Investigator: Chunhong Shen, Second Affiliated Hospital, School of Medicine, Zhejiang University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2023
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2033

Study Registration Dates

• First Submitted: April 16, 2024
• First Submitted That Met QC Criteria: April 24, 2024
• First Posted (Actual): April 29, 2024

Study Record Updates

• Last Update Posted (Estimated): August 27, 2025
• Last Update Submitted That Met QC Criteria: August 20, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epilepsy; Epilepsy, Idiopathic Generalized
• Other Study ID Numbers: S2022-0336

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• product manufactured in and exported from the U.S.: No